Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

3(37.5%)

Phase 2

2(25.0%)

Phase 1

2(25.0%)

N/A

1(12.5%)

8Total

Phase 3(3)

Phase 2(2)

Phase 1(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00007670Phase 3Completed

Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.

Role: collaborator

NCT00600106Not ApplicableCompleted

Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study

Role: collaborator

NCT00283335Phase 3Completed

The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

Role: collaborator

NCT00492037Phase 3Completed

Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia

Role: collaborator

NCT00005624Phase 2Completed

CI-994 in Treating Patients With Advanced Myeloma

Role: collaborator

NCT00116545Phase 2Completed

TART - Troglitazone Atherosclerosis Regression Trial

Role: lead

NCT00002218Phase 1Completed

A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients

Role: lead

NCT00002196Phase 1Completed

A Study of CI-1012 in HIV-Infected Patients

Role: lead

All 8 trials loaded